These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 3446241)

  • 21. Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma.
    Blank O; von Tresckow B; Monsef I; Specht L; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD007110. PubMed ID: 28447341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Missing data mechanisms in a dose-finding adaptive trial.
    Liu K; Entsuah R
    J Biopharm Stat; 2012; 22(2):329-37. PubMed ID: 22251177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of prognostic factors in clinical trials.
    Sather HN
    Cancer; 1986 Jul; 58(2 Suppl):461-7. PubMed ID: 3719540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Why data bases should not replace randomized clinical trials.
    Byar DP
    Biometrics; 1980 Jun; 36(2):337-42. PubMed ID: 7407321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Planned interim analysis and its role in cancer clinical trials.
    Geller NL
    J Clin Oncol; 1987 Sep; 5(9):1485-90. PubMed ID: 3625263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bias and loss: the two sides of a biased coin.
    Atkinson AC
    Stat Med; 2012 Dec; 31(28):3494-503. PubMed ID: 22736426
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized clinical trials in the evaluation of surgical innovation.
    Haines SJ
    J Neurosurg; 1979 Jul; 51(1):5-11. PubMed ID: 376786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Use of prognostic knowledge in the planning and analysis of randomized therapeutic trials].
    Byar D; Chastang C
    Bull Cancer; 1987; 74(2):177-84. PubMed ID: 3607300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence-based medicine, systematic reviews, and guidelines in interventional pain management: Part 2: Randomized controlled trials.
    Manchikanti L; Hirsch JA; Smith HS
    Pain Physician; 2008; 11(6):717-73. PubMed ID: 19057624
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A tentative of guideline for phase III study and its problems in clinical aspect].
    Nakao I
    Gan To Kagaku Ryoho; 1984 Mar; 11(3):395-403. PubMed ID: 6703719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment allocation methods in clinical trials: a review.
    Kalish LA; Begg CB
    Stat Med; 1985; 4(2):129-44. PubMed ID: 3895341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reporting results from chemotherapy trials. Does response make a difference in patient survival?
    Oye RK; Shapiro MF
    JAMA; 1984 Nov; 252(19):2722-5. PubMed ID: 6387202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The practical aspects of clinical trials of contraceptive methods.
    Weisberg E
    Clin Reprod Fertil; 1986 Apr; 4(2):139-47. PubMed ID: 3527399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response adaptive designs with a variance-penalized criterion.
    Yi Y; Wang X
    Biom J; 2009 Oct; 51(5):763-73. PubMed ID: 19757432
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis.
    Lueza B; Rotolo F; Bonastre J; Pignon JP; Michiels S
    BMC Med Res Methodol; 2016 Mar; 16():37. PubMed ID: 27025706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of multiple comparisons in randomized clinical trials.
    Smith DG; Clemens J; Crede W; Harvey M; Gracely EJ
    Am J Med; 1987 Sep; 83(3):545-50. PubMed ID: 3661589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patient subsets and variation in therapeutic efficacy.
    Simon R
    Br J Clin Pharmacol; 1982 Oct; 14(4):473-82. PubMed ID: 7138732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of Adjusted and Unadjusted Indirect Comparison Methods in Benefit Assessment. A Simulation Study for Time-to-event Endpoints.
    Kühnast S; Schiffner-Rohe J; Rahnenführer J; Leverkus F
    Methods Inf Med; 2017 May; 56(3):261-267. PubMed ID: 28361159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Compliance in clinical trials: impact on design, analysis and interpretation.
    Pledger GW
    Epilepsy Res Suppl; 1988; 1():125-33. PubMed ID: 3072187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of clinical trials in gynecologic cancer--timing and interpretation.
    Blessing JA; Anderson B
    Gynecol Oncol; 1986 Mar; 23(3):275-83. PubMed ID: 3514389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.